Skip to content
March 28, 2024

Equity.Guru

Investment information for the new generation

Search

Shroom Boom

Xphyto describes itself as “a bioscience accelerator” “targeting growth through commercialization of its product pipeline”….
Core One Labs (COOL.C) subsidiary Vocan Biotechnologies finished putting together the required equipment to start artificially producing psilocybin today, according to a press release. Acquired in December, Vocan has…
Revive Therapeutics (RVV.C) and 17 other companies in the United States and Canada joined the first psychedelic exchange-traded fund, managed by Horizons ETF management today, according to a press…
If we’re honest about it – if we’re REALLY honest about it – Canada has fumbled its advantage in the cannabis sector. First to market, first to raise hundreds…
In lieu of the American markets not opening today courtesy of the civic holiday, Xphyto Therapeutics (XPHY.C) has elected to provide a glimpse into their business strategy and milestones…
Revive Therapeutics (RVV.C) entered into a sponsored research agreement and license agreement with North Carolina State University (NC State), developing a biosynthetic version of psilocybin today, according to a…
Core One’s objective in developing the psilocybin thinstrips is to assist with the delivery of revolutionary psychedelic treatment methods to address mental health conditions such as depression, anxiety and…
The company’s platform includes “The Delic”, an e-commerce lifestyle brand, “Reality Sandwich”, a free public education platform and “Meet Delic” – a psychedelic wellness summit with its first planned…
“This transaction will significantly enhance Core One Labs’ ability to innovate our psychedelic drug development program,” stated Joel Shacker, CEO of Core Labs….
The notion of magic mushroom market offering after the legalization of cannabis has been floated time and again since long before cannabis legalization was even on the table. It…